Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma and Persistent Sputum Eosinophilia Despite Standard Dose Therapy

NCT04710134 is registered in ClinicalTrials.gov with McMaster University as lead sponsor.

NCT NCT04710134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04710134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma and Persistent Sputum Eosinophilia Despite Standard Dose Therapy
Lead sponsor
McMaster University
Phase
Phase 4
Overall status
Completed
Start date
February 10, 2021
Completion date
January 9, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma; eosinophilic